StockData
Agilent Technologies, Inc. logo

Agilent Technologies, Inc.

ANYSELaboratory Analytical InstrumentsFiscal year ends October 31
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 1, 2026Score 21/3020% above fair value
$170.38−4.96 (-2.83%)

Close on Nov 20, 2026Market cap $48.04BP/E 33.6Yield 0.58%

Agilent Technologies FDA MAUDE Adverse Event Reports by Quarter

FDA MAUDE Adverse Event Reports — Agilent Technologies & Dako Total (reports)

Periods

Agilent Technologies FDA MAUDE Adverse Event Reports: 3 in Q3 FY26, down 70.0% from a year earlier.

Latest, Q3 FY26
3
Period ended Jul 31, 2026 (CQ2 2026)
Change on a year earlier
-70.0%
10 in Q3 FY25
History
43 quarters
Since Q1 FY16
Sources
1
U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total)

Where the Q3 FY26 figure comes from

Source: U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗

Reported in U.S. Food & Drug Administration (openFDA API).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFDA MAUDE Adverse Event Reports — Agilent Technologies & Dako Total (reports)Year on yearSource
Q3 FY26CQ2 2026Jul 31, 20263-70.0%U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗
Q2 FY26CQ1 2026Apr 30, 20261-96.3%U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗
Q1 FY26CQ4 2025Jan 31, 20263-88.5%U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗
Q4 FY25CQ3 2025Oct 31, 20256-68.4%U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗
Q3 FY25CQ2 2025Jul 31, 202510-47.4%U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗
Q2 FY25CQ1 2025Apr 30, 202527+22.7%U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗
Q1 FY25CQ4 2024Jan 31, 202526+4.0%U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗
Q4 FY24CQ3 2024Oct 31, 202419+137.5%U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗
Q3 FY24CQ2 2024Jul 31, 202419-34.5%U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗
Q2 FY24CQ1 2024Apr 30, 202422-56.0%U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗
Q1 FY24CQ4 2023Jan 31, 202425-30.6%U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗
Q4 FY23CQ3 2023Oct 31, 20238-76.5%U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗
Q3 FY23CQ2 2023Jul 31, 202329+7.4%U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗
Q2 FY23CQ1 2023Apr 30, 202350+2.0%U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗
Q1 FY23CQ4 2022Jan 31, 202336+33.3%U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗
Q4 FY22CQ3 2022Oct 31, 202234-8.1%U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗

Breakdown

What makes up FDA MAUDE Adverse Event Reports

Cite this data

StockData. (2026). Agilent Technologies FDA MAUDE Adverse Event Reports, quarterly Q1 FY16–Q3 FY26 [Data set]. Compiled from Agilent Technologies SEC filings and investor materials. https://stockdatahq.com/stocks/a/kpis/fda-maude-total

See every metric in the Agilent Technologies KPI table. Data updated Nov 8, 2026.

See a number that looks wrong?